Paul Choi
Stock Analyst at Goldman Sachs
(3.51)
# 695
Out of 4,814 analysts
108
Total ratings
52.17%
Success rate
2.46%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $35.16 | +47.92% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $5.47 | +284.26% | 8 | Apr 17, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $22 → $16 | $9.67 | +65.46% | 3 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $5.96 | +101.34% | 3 | Apr 17, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $12 → $10 | $4.08 | +145.10% | 9 | Apr 17, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $8 → $7 | $0.84 | +728.70% | 5 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $0.96 | +211.24% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $10.30 | -2.91% | 4 | Apr 17, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $15 → $12 | $8.60 | +39.53% | 2 | Apr 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $20 → $7 | $9.24 | -24.20% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $160.53 | +40.17% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $101.32 | +41.14% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $47.45 | -11.49% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $39.48 | +51.98% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $13.74 | +38.28% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $20.21 | +58.34% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $34.24 | +46.03% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $3.78 | +402.65% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $0.29 | +587.29% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.00 | +2,400.00% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $4 | $0.33 | +1,125.87% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $20.35 | +735.38% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $2.86 | +179.72% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $29.10 | +13.40% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $37.89 | +195.59% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $100.10 | +34.87% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $0.64 | +3,025.00% | 2 | Mar 30, 2020 |
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $35.16
Upside: +47.92%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.47
Upside: +284.26%
UroGen Pharma
Apr 17, 2025
Maintains: Neutral
Price Target: $22 → $16
Current: $9.67
Upside: +65.46%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $5.96
Upside: +101.34%
Phathom Pharmaceuticals
Apr 17, 2025
Maintains: Neutral
Price Target: $12 → $10
Current: $4.08
Upside: +145.10%
Gossamer Bio
Apr 17, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.84
Upside: +728.70%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $0.96
Upside: +211.24%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $10.30
Upside: -2.91%
Arvinas
Apr 17, 2025
Maintains: Neutral
Price Target: $15 → $12
Current: $8.60
Upside: +39.53%
Amarin Corporation
Apr 17, 2025
Maintains: Sell
Price Target: $20 → $7
Current: $9.24
Upside: -24.20%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $160.53
Upside: +40.17%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $101.32
Upside: +41.14%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $47.45
Upside: -11.49%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $39.48
Upside: +51.98%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $13.74
Upside: +38.28%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $20.21
Upside: +58.34%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $34.24
Upside: +46.03%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $3.78
Upside: +402.65%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.29
Upside: +587.29%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.00
Upside: +2,400.00%
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $0.33
Upside: +1,125.87%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $20.35
Upside: +735.38%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $2.86
Upside: +179.72%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $29.10
Upside: +13.40%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $37.89
Upside: +195.59%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $100.10
Upside: +34.87%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $0.64
Upside: +3,025.00%